Search

everythinglearnresearchcommunity

for

Search:↓

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.

Long-term use of a certain medication can worsen erectile function in aged rats by damaging penile muscle cells.

5α-reductase inhibitors may worsen sexual drive and spontaneous erections but don't worsen existing erectile or ejaculatory problems.

Urologic diseases and treatments in older men can negatively affect fertility, and doctors should talk to patients about this.

Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.

Using 5α-reductase inhibitors for hair loss can cause lasting sexual, physical, mental, and vascular health issues in men, even after stopping the medication.

The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.

COVID-19 may worsen with androgens; anti-androgen drugs could help.

5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.

New treatments for male hypogonadism are effective and should be personalized.

Some hair loss and prostate drugs might increase the risk of diabetes and heart disease.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.

5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.

Finasteride reduces prostate size and serum levels, helping manage benign prostatic hyperplasia, without affecting prostate cancer detection. Regular monitoring is needed for users.

Taking 5α-reductase inhibitors with prednisolone can worsen its negative effects on metabolism.

New testosterone analogs show promise for male contraception with better activity and potentially fewer side effects.

5-alpha reductase inhibitors may reduce bladder cancer recurrence and improve survival.

Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.

Finasteride irreversibly affects human steroid 5α-reductase 2, providing insight into its catalytic mechanism and disease-related mutations.

A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.

Combination therapies work better than single treatments for hair loss.

Dutasteride may help stabilize Frontal Fibrosing Alopecia, but more research is needed.

Dutasteride more effectively treats hair loss than finasteride, but may increase risk of altered libido.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

Lovastatin doesn't improve lower urinary tract symptoms treatment.

Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.

Nandrolone might increase muscle mass with fewer side effects than testosterone but could cause erectile dysfunction and needs more research.

Hesperidin protects rat testicles from finasteride damage and improves sperm health.